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Background
Ad5-GUCY2C-PADRE is a replication-deficient human
type 5 recombinant adenovirus (Ad5) vaccine encoding
guanylyl cyclase C (GUCY2C) fused to the PAn DR Epi-
tope (PADRE). GUCY2C, a paracrine hormone receptor
producing the second messenger cyclic GMP (cGMP), is
selectively expressed by intestinal epithelial cells and a
subset of hypothalamic neurons, but not other tissues.
Importantly, GUCY2C is over-expressed in nearly all pri-
mary and metastatic human colorectal tumors. Preclinical
studies in mice demonstrated selective tolerance of
GUCY2C-specific CD4+ T cells, but not CD8+ T or
B cells, necessitating inclusion of the exogenous CD4+
T helper cell epitope PADRE to maximize GUCY2C-
specific CD8+ T cell and antibody responses and antitu-
mor efficacy, without autoimmunity.
Patients and methods
This is an open-label, single arm “proof-of-concept” study
evaluating a single dose level of Ad5-GUCY2C-PADRE as
a vaccine for surgically-treated, node-negative colon can-
cer subjects (NCT01972737). Patients received a single
intramuscular administration of 1011 Ad5-GUCY2C-
PADRE viral particles. Safety and immunomonitoring
where examined at 30, 90 and 180 days following vaccina-
tion. Primary objectives were to determine the safety, tol-
erability and toxicity of Ad5-GUCY2C-PADRE and to
determine whether Ad5-GUCY2C-PADRE induces
GUCY2C-specific immune responses. The study employed
a joint efficacy-toxicity design and included stopping rules
for either efficacy or toxicity. Results here were obtained
during the planned interim analysis following accrual of
10 subjects.
Results
The vaccine was well tolerated, producing only mild
adverse events (AEs). Short-lived injection site pain/swel-
ling, body aches and chills were the most commonly
observed AEs and occurred in 30-40% of subjects.
GUCY2C-specific antibody and T-cell responses were
observed in a subset of subjects. Consistent with preclini-
cal mouse data, T-cell responses were composed of CD8+,
but not CD4+, T cells. Importantly, GUCY2C-specific
responses occurred only in subjects with low Ad5 neutra-
lizing antibody (NAb) titers at the time of vaccination,
suggesting that pre-existing Ad5 immunity limits
Ad5-GUCY2C-PADRE immunogenicity.
Conclusions
Interim analysis of 10 subjects receiving Ad5-GUCY2C-
PADRE demonstrates proof-of-concept that GUCY2C is
immunogenic in humans and that GUCY2C-directed
vaccination is safe. Moreover, the presence of GUCY2C-
specific antibody and CD8+ T-cell, but not CD4+ T-cell,
responses is consistent with selective CD4+ T-cell toler-
ance observed in mouse models. These data establish
GUCY2C as a safe and immunogenic target for immu-
notherapy in cancer patients.
Trial registration
ClincialTrials.gov identifier NCT01972737.
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